#United States #Hanover #Nitrogen Dioxide #Noxilizer #NewVale Capital

Noxilizer Strengthens a Game-Changer in Sterilization Technology

Noxilizer, Inc., a pioneering company in nitrogen dioxide (NO₂)-based terminal sterilization, is taking a significant step forward by securing $30 million in growth capital. This funding, spearheaded by NewVale Capital, is aimed at expanding its sterilization services for the biopharmaceutical and medical device industries. This investment comes at a crucial time when the market demands effective alternatives to conventional sterilization methods like ethylene oxide (EtO).

The Need for Change in Sterilization Methods

The healthcare landscape is rapidly evolving, with an increasing need for validated and commercially viable sterilization methods that prioritize safety and sustainability. Traditional methods such as ethylene oxide sterilization have faced scrutiny and regulatory constraints, driving demand for effective alternatives. Noxilizer's nitrogen dioxide sterilization platform stands out as a viable solution that is already trusted by leading pharmaceutical and biotech companies for the sterilization of critical drug-device combinations.

Christopher Thatcher, Noxilizer's President and CEO, expressed his enthusiasm about this funding. He stated, "This investment allows us to broaden the availability of NO₂ sterilization at a time when manufacturers urgently need validated, commercial-ready alternatives to existing methods." Noxilizer is committed to providing a platform that not only meets current industrial demands but also adheres to the highest safety and regulatory standards.

Features of Noxilizer's NO₂ Sterilization Platform

The NO₂ sterilization platform is noted for its comprehensive attributes that enhance sterilization processes:

• - Commercial and Regulatory Validation: Noxilizer's platform has received approval from global regulatory authorities and is utilized in marketed biopharmaceutical products, verifying its effectiveness.
• - Safety and Sustainability: Unlike EtO, nitrogen dioxide is non-carcinogenic, with its emissions adhering to room air quality standards, thus representing a safer option for sterilization.
• - Compatibility: The platform is effective for sensitive biologics and various drug-device combinations.
• - Efficiency and Scale: Noxilizer's sterilization method is fast, easy to implement in-house, and supports supply chain reliability.

With these features, Noxilizer presents itself as one of the most promising alternatives to existing methods in the market today.

Looking Ahead with NewVale Capital

Todd Holmes, the Founder and Managing Partner of NewVale Capital, underlined the strategic importance of this investment: "The platform has already been adopted by a growing list of leading manufacturers, and we're excited to support Noxilizer through its next phase of expansion to meet the rising demand for sustainable, next-generation sterilization."

The collaboration with NewVale Capital not only secures necessary investment but also signifies a commitment to innovation and excellence in the sterilization sector. The additional capital will empower Noxilizer to reach a wider audience and enhance its operational capacity, ensuring that their clients have access to top-tier sterilization technologies in a rapidly changing healthcare environment.

About Noxilizer

Headquartered in Hanover, Maryland, Noxilizer specializes in ultra-low temperature nitrogen dioxide terminal sterilization tailored for the pharmaceutical, biotechnology, and medical device sectors. With FDA approvals and endorsements from leading global manufacturers, Noxilizer offers extensive services, including RD studies, packaging consultation, and ongoing customer support alongside its proprietary sterilization equipment. Their continued growth and commitment to innovation position them favorably in the booming life sciences industry.

In Summary

As Noxilizer embarks on this new chapter with the backing of NewVale Capital, the company is set to become a key player in the transition towards safer, more sustainable sterilization solutions. This move reflects not only the growing demand in the sector but also a proactive approach towards meeting contemporary sterilization needs efficiently and responsibly.